Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

Monk PD., Marsden RJ., Tear VJ., Brookes J., Batten TN., Mankowski M., Gabbay FJ., Davies DE., Holgate ST., Ho L-P., Clark T., Djukanovic R., Wilkinson TMA., Crooks MG., Dosanjh DPS., Siddiqui S., Rahman NM., Smith JA., Horsley A., Harrison TW., Saralaya D., McGarvey L., Watson A., Foster E., Fleet A., Singh D., Hemmings S., Aitken S., Dudley S., Beegan R., Thompson A., Rodrigues PMB.

DOI

10.1016/s2213-2600(20)30511-7

Type

Journal article

Publisher

Elsevier BV

Publication Date

2021-02-01T00:00:00+00:00

Volume

9

Pages

196 - 206

Total pages

10

Permalink More information Close